Skip to main content

Cardiol Therapeutics Inc Purchase WT(CRDL-WT-A-T)
TSX

Today's Change
Real-Time Last Update

Cardiol Therapeutics Inc Purchase WT

2265 Upper Middle Road East
Suite 602
Oakville ON L6H 0G5 CAN
P: 289-910-0850
https://www.cardiolrx.com

Sectors & Indices

Sector
Industry
Employees

    Profile

    Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

    Key Executives

    NameTitle
    Christopher J. WaddickCFO/Director/Secretary
    David G. ElsleyCEO/Director/President
    Andrew HamerChief Medical Officer
    Bernard LimCOO

    More from The Globe